{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:55:44Z","timestamp":1791932144754,"version":"4.3.4"},"reference-count":26,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Smoking is a recognized risk factor for Graves' disease (GD), but its quantitative relationship with disease severity, autoimmunity, and relapse after antithyroid drug (ATD) therapy is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the dose-dependent association between smoking exposure and key clinical outcomes in GD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center observational cohort study conducted in a secondary-care endocrinology unit in the United Kingdom. Consecutive adults with newly diagnosed GD confirmed by suppressed TSH, elevated thyroid hormones, and positive TRAb or diffusely increased scintigraphic uptake were analysed. All 991 eligible patients were included in baseline analyses; 663 completed \u226512 months follow-up after ATD cessation, and 712 contributed to long-term relapse analyses. The main outcome measures were baseline TRAb levels, presence of orbitopathy, and relapse at 12 months and long term, defined as recurrent biochemical hyperthyroidism with elevated TRAb after ATD withdrawal. Other outcomes included additional biochemical, scintigraphic and clinical measures. Exposures were smoking status (non-, ex-, current smoker) and cigarettes\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current smokers (27%) had higher TRAb levels at diagnosis (median 7.8 vs 6.6 IU\/L in nonsmokers, P = .002) and increased odds of orbitopathy (OR 1.76, 95% CI 1.17-2.64). Each 10 cigarettes\/day conferred a 34% (95% CI 10-79%) higher odds of orbitopathy and 60% higher 12-month relapse risk. Smokers also had higher TRAb at ATD cessation. In time-dependent Cox models, excess relapse risk among current smokers was greatest early after ATD withdrawal (HR 1.24 at 6 months) and diminished by 2 years. TRAb mediated only 7% of the smoking\u2013relapse association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Smoking is associated with greater autoimmune activity, higher orbitopathy risk, and increased relapse in a dose-dependent manner. Ex-smokers have risks comparable with nonsmokers, supporting cessation or reduction as a meaningful intervention to improve GD outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag061","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:48:22Z","timestamp":1770814102000},"page":"e1805-e1812","source":"Crossref","is-referenced-by-count":4,"title":["Cigarette smoking exposure and clinical outcomes in Graves' disease"],"prefix":"10.1210","volume":"111","author":[{"given":"Sarah","family":"Forbes","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Loo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ann","family":"Tee","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Vernazza","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, South of Tyne Pathology Services, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, South of Tyne Pathology Services, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Vennart","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, South Tyneside and Sunderland NHS Foundation Trust , Sunderland SR4 7TP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartholomew","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, South Tyneside and Sunderland NHS Foundation Trust , Sunderland SR4 7TP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilimangalam","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Tsatlidis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-1556","authenticated-orcid":false,"given":"Salman","family":"Razvi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gateshead Health NHS Foundation Trust , Gateshead NE9 6SX ,","place":["UK"]},{"name":"Translational and Clinical Research Institute, Centre for Life, Newcastle University, Central Parkway , Newcastle upon Tyne NE1 3BZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"16","key":"2026061619573461000_dgag061-B1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2026061619573461000_dgag061-B2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.2023.19052","article-title":"Hyperthyroidism: a review","volume":"330","author":"Lee","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"2026061619573461000_dgag061-B3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves' disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"2026061619573461000_dgag061-B4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/105072502753451995","article-title":"Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism","volume":"12","author":"Vestergaard","year":"2002","journal-title":"Thyroid"},{"issue":"5","key":"2026061619573461000_dgag061-B5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"Glinoer","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026061619573461000_dgag061-B6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archinte.160.5.661","article-title":"Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study","volume":"160","author":"Brix","year":"2000","journal-title":"Arch Intern Med"},{"issue":"14","key":"2026061619573461000_dgag061-B7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/archinte.165.14.1606","article-title":"Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism","volume":"165","author":"Holm","year":"2005","journal-title":"Arch Intern Med"},{"issue":"8","key":"2026061619573461000_dgag061-B8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/s-2006-924065","article-title":"Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs","volume":"114","author":"Quadbeck","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"2026061619573461000_dgag061-B9","doi-asserted-by":"crossref","first-page":"101387","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves' disease: epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2026061619573461000_dgag061-B10","first-page":"403","article-title":"Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts\u2014a possible explanation of the link between smoking and Graves' ophthalmopathy","volume":"7","author":"Chng","year":"2014","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"2026061619573461000_dgag061-B11","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clinthera.2020.01.022","article-title":"Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis","volume":"42","author":"Shi","year":"2020","journal-title":"Clin Ther"},{"issue":"8","key":"2026061619573461000_dgag061-B12","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/thy.2016.0017","article-title":"Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse","volume":"26","author":"Tun","year":"2016","journal-title":"Thyroid"},{"issue":"6","key":"2026061619573461000_dgag061-B13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for Graves' hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"issue":"8","key":"2026061619573461000_dgag061-B14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026061619573461000_dgag061-B15","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026061619573461000_dgag061-B16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: the fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2026061619573461000_dgag061-B17","doi-asserted-by":"crossref","first-page":"R241","DOI":"10.1530\/EJE-14-0047","article-title":"Mechanisms in endocrinology: autoimmune thyroid disease: old and new players","volume":"170","author":"Effraidimis","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026061619573461000_dgag061-B18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000443373","article-title":"Adjuvant treatment of Graves' disease with diclofenac: safety, effects on opthalmopathy and antibody concentrations","volume":"5","author":"Lantz","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2026061619573461000_dgag061-B19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jama.2008.931","article-title":"Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs non-smokers with Graves' disease treated with carbimazole","volume":"301","author":"Nyirenda","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"2026061619573461000_dgag061-B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"8000","key":"2026061619573461000_dgag061-B21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06968-8","article-title":"Smoking changes adaptive immunity with persistent effects","volume":"626","author":"Saint-Andre","year":"2024","journal-title":"Nature"},{"issue":"7","key":"2026061619573461000_dgag061-B22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026061619573461000_dgag061-B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jc.2006-1824","article-title":"Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link","volume":"92","author":"Cawood","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026061619573461000_dgag061-B24","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1210\/jc.2007-0675","article-title":"Association between a C\/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves' hyperthyroidism after antithyroid withdrawal in Taiwanese","volume":"92","author":"Hsio","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026061619573461000_dgag061-B25","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.25011\/cim.v32i3.6108","article-title":"Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil","volume":"32","author":"Cinemre","year":"2009","journal-title":"Clin Invest Med"},{"issue":"4","key":"2026061619573461000_dgag061-B26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000342621","article-title":"Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawal","volume":"1","author":"Wang","year":"2013","journal-title":"Eur Thyroid J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag061\/66863227\/dgag061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1805\/66863227\/dgag061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1805\/66863227\/dgag061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:40Z","timestamp":1781654260000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1805\/8475164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag061","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,12]]}}}